Certain compounds inside kratom are more potent than morphine in lab tests, but kratom leaf as people actually consume it is not stronger than morphine. The distinction comes down to what happens between a purified alkaloid in a test tube and a dried leaf brewed into tea or swallowed as powder. Understanding why requires a look at kratom’s active chemicals, how they behave at opioid receptors, and what that means for both pain relief and risk.
The Alkaloids That Drive the Comparison
Kratom leaves contain dozens of active compounds, but two matter most for this question: mitragynine and 7-hydroxymitragynine (often shortened to 7-OH). Mitragynine is the dominant alkaloid, making up roughly 1 to 2.5% of dried leaf weight. The concentration varies widely depending on the plant’s genetics and growing region, with one large study of Thai kratom finding mitragynine content ranging from about 7.5 to 26.6 milligrams per gram of dry leaf. 7-hydroxymitragynine is present in much smaller amounts.
In isolated lab preparations, 7-hydroxymitragynine is about 13 times more potent than morphine. A third compound, mitragynine pseudoindoxyl, which forms when 7-hydroxymitragynine is metabolized in human blood plasma, is roughly 20 times more potent than morphine. These are striking numbers, and they’re where the “stronger than morphine” claim originates.
But potency in a lab assay measures how strongly a purified molecule binds to a receptor or inhibits a tissue response. It doesn’t account for how much of that molecule you actually absorb when you chew a leaf or drink a kratom tea.
Why Kratom Leaf Isn’t Equivalent to Morphine
The key reason is concentration. Mitragynine dominates kratom’s alkaloid profile, accounting for roughly 28 to 69% of total alkaloids depending on the plant. 7-hydroxymitragynine, the compound that outperforms morphine in lab tests, is present only in trace amounts in raw leaf material. So while that molecule is potent in isolation, a typical serving of kratom powder delivers very little of it.
There’s also a fundamental difference in how these compounds activate opioid receptors. Morphine is a full agonist at the mu-opioid receptor, meaning it can push the receptor’s response all the way to maximum. Mitragynine and 7-hydroxymitragynine are partial agonists. In tests on human mu-opioid receptors, mitragynine reached only about 34% of the maximum response that a full agonist produces. Think of it like a dimmer switch that can only turn the light up partway, no matter how far you push. This partial activation places a hard limit on how strong the effects can get, even at high doses.
The Built-In Ceiling Effect
This partial agonism creates something researchers call a ceiling effect, which has important implications for both pain relief and safety. In mouse studies, mitragynine at 10 mg per kilogram of body weight caused noticeable respiratory depression, the slowed breathing that makes opioid overdoses deadly. But tripling that dose to 30 mg, or pushing it to 90 mg, produced no additional respiratory depression. The effect simply plateaued.
Morphine doesn’t work this way. As the dose climbs, breathing slows further and further, which is why morphine overdoses can be fatal. With mitragynine, the body’s response appears to hit a wall. No fatal case of kratom-induced respiratory depression has been reported in the scientific literature to date, though kratom has been listed as a contributing factor in deaths involving multiple substances.
When researchers compared oral doses of mitragynine, 7-hydroxymitragynine, and morphine calibrated to produce equivalent pain relief, all three suppressed breathing to a similar degree over the full observation period. The takeaway: at doses that relieve about the same amount of pain, the respiratory risk looks comparable, but morphine’s risk keeps climbing with dose while mitragynine’s levels off.
Biased Signaling and Reduced Side Effects
Kratom’s alkaloids interact with opioid receptors in an unusual way. Beyond being partial agonists, they preferentially activate one specific signaling pathway (the G protein pathway) while largely avoiding another pathway linked to side effects like severe constipation, respiratory depression, and the intense euphoria that drives addiction. This selective activation, called biased signaling, is why pharmacologists are studying kratom’s molecular structure as a potential blueprint for safer pain medications.
Mitragynine and 7-hydroxymitragynine also block kappa and delta opioid receptors rather than activating them. Kappa receptor activation is associated with feelings of unease and dissatisfaction, so blocking it may partly explain why kratom’s subjective experience differs from that of traditional opioids.
Pain Relief in Practice
People who use kratom for pain typically report effects that are real but milder than prescription opioids. This tracks with the pharmacology: a partial agonist that reaches only a third of a full agonist’s maximum response will produce a less intense effect. For someone with moderate chronic pain who wants to avoid or step down from prescription opioids, that may be exactly the point. For someone in severe post-surgical pain, kratom would not substitute for morphine.
There are no controlled clinical trials establishing a dose-equivalence chart between grams of kratom and milligrams of morphine, so any conversion you see online is anecdotal. The wide natural variation in alkaloid content, from about 1% to over 2.5% mitragynine by weight, means that two batches of kratom powder can differ dramatically in strength.
Dependence and Withdrawal
Kratom does cause physical dependence with regular use. It acts on the same receptors as morphine, and the body adapts accordingly. However, clinical observations suggest the withdrawal syndrome is less intense than withdrawal from prescription opioids, though it tends to last longer. Reported symptoms include runny nose, insomnia, difficulty concentrating, muscle aches, and low mood, persisting for around 10 days after the last dose in documented cases. By comparison, acute opioid withdrawal from drugs like morphine or oxycodone typically peaks in severity within 2 to 3 days, with the worst physical symptoms resolving within a week.
The Bottom Line on Potency
Isolated kratom alkaloids can outperform morphine molecule-for-molecule in receptor binding tests, with one metabolite reaching 20 times morphine’s potency. But kratom as consumed is a dilute plant material containing mostly mitragynine, a partial agonist that tops out at about a third of morphine’s maximum receptor activation. The result is a substance that acts on the same system as morphine, produces genuine opioid-like effects including pain relief and dependence, but operates with a lower ceiling for both benefit and harm. Calling kratom “stronger than morphine” is technically true for one minor alkaloid in a lab dish and misleading for everything else.